PMID- 31974533
OWN - NLM
STAT- MEDLINE
DCOM- 20220225
LR  - 20220225
IS  - 1804-7521 (Electronic)
IS  - 1213-8118 (Linking)
VI  - 165
IP  - 2
DP  - 2021 Jun
TI  - The impact of riociguat on clinical parameters and quality of life in patients 
      with chronic thromboembolic pulmonary hypertension - results of a retrospective 
      clinical registry.
PG  - 157-161
LID - 10.5507/bp.2019.061 [doi]
AB  - AIMS: The primary objective of the registry was to assess the impact of riociguat 
      on clinical parameters and quality of life in patients with chronic 
      thromboembolic pulmonary hypertension (CTEPH) that was inoperable or 
      persistent/recurrent after pulmonary endarterectomy (PEA). In contrast to 
      randomized pivotal trials, this non-interventional registry evaluated the 
      effectiveness and safety of riociguat in a real-world setting. METHODS: 
      Retrospective data were collected from patients' charts as recorded in routine 
      clinical practice from the initiation of riociguat therapy up to approximately 5 
      months and 1 year after this initiation. RESULTS: In total, 51 patients from a 
      single site were enrolled. After 5 months (mean duration) of riociguat treatment, 
      the following improvements from baseline were observed: change of distance in the 
      6-minute walking distance (6MWD) (P=0.066); change of score from the quality of 
      life questionnaire (EQ5D-5L) (P=0.020), and overall self-assessment of health 
      status (P=0.001). New York Heart Association (NYHA) class improved in 24.3% of 
      patients. After 11.2 months (mean duration) of riociguat treatment, the following 
      improvements from baseline were observed: change of distance in the 6MWD test 
      (P=0.006), and overall self-assessment of health status (P=0.009). NYHA class 
      improved in 46.4% of patients. Riociguat was well tolerated. In total, 4 patients 
      reported side effects, with hospitalization required in one case and 2 patients 
      who had to discontinue the treatment. Annual survival rate was 89.1%. CONCLUSION: 
      Riociguat improves functional NYHA class, distance in the 6MWD test and quality 
      of life in a real-world patient population.
FAU - Jansa, Pavel
AU  - Jansa P
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, Czech 
      Republic.
FAU - Ambroz, David
AU  - Ambroz D
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, Czech 
      Republic.
FAU - Kuchar, Jan
AU  - Kuchar J
AD  - Department of Cardiology, Tabor Hospital, Inc., Czech Republic.
FAU - Dytrych, Vladimir
AU  - Dytrych V
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, Czech 
      Republic.
FAU - Lindner, Jaroslav
AU  - Lindner J
AD  - 2nd Department of Surgery - Department of Cardiovascular Surgery, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, Czech 
      Republic.
FAU - Linhart, Ales
AU  - Linhart A
AD  - 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty 
      of Medicine, Charles University and General University Hospital in Prague, Czech 
      Republic.
LA  - eng
PT  - Journal Article
DEP - 20200120
PL  - Czech Republic
TA  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
JT  - Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, 
      Czechoslovakia
JID - 101140142
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - RU3FE2Y4XI (riociguat)
SB  - IM
MH  - Chronic Disease
MH  - Humans
MH  - *Hypertension, Pulmonary/drug therapy/etiology
MH  - *Pulmonary Embolism/complications/drug therapy
MH  - Pyrazoles
MH  - Pyrimidines
MH  - Quality of Life
MH  - Registries
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - chronic thromboembolic pulmonary hypertension
OT  - clinical parameters
OT  - quality of life
OT  - real-world population
OT  - riociguat
EDAT- 2020/01/25 06:00
MHDA- 2022/02/26 06:00
CRDT- 2020/01/25 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2019/12/13 00:00 [accepted]
PHST- 2020/01/25 06:00 [pubmed]
PHST- 2022/02/26 06:00 [medline]
PHST- 2020/01/25 06:00 [entrez]
AID - 10.5507/bp.2019.061 [doi]
PST - ppublish
SO  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Jun;165(2):157-161. 
      doi: 10.5507/bp.2019.061. Epub 2020 Jan 20.